Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a note issued to investors on Tuesday. The brokerage set a “strong-buy” rating on the stock.

Separately, Truist Financial boosted their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $19.51 on Tuesday. The company’s 50-day moving average is $20.83 and its 200 day moving average is $20.23. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.14 and a current ratio of 1.50. The company has a market capitalization of $11.45 billion, a P/E ratio of 21.92, a price-to-earnings-growth ratio of 1.04 and a beta of 0.93. Fresenius Medical Care has a fifty-two week low of $16.37 and a fifty-two week high of $27.72.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.10. The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.15 billion. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. On average, equities research analysts forecast that Fresenius Medical Care will post 1.5 earnings per share for the current year.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. increased its position in shares of Fresenius Medical Care by 14,252.1% during the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after buying an additional 484,998 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Fresenius Medical Care by 362.2% during the third quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock valued at $5,580,000 after buying an additional 202,991 shares during the period. Moran Wealth Management LLC bought a new stake in shares of Fresenius Medical Care during the fourth quarter valued at about $3,247,000. Guardian Capital Advisors LP increased its position in shares of Fresenius Medical Care by 16.7% during the fourth quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock valued at $2,556,000 after buying an additional 17,725 shares during the period. Finally, Partnership Wealth Management LLC bought a new stake in shares of Fresenius Medical Care during the fourth quarter valued at about $2,340,000. 8.25% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.